Adherence support for metastatic breast cancer patients
Part of Cancer, Skin clinical trials.
This study tests a program to help people with metastatic breast cancer take their endocrine therapy, CDK4/6 inhibitors, and heart-related medications as prescribed. If you sometimes miss doses of these medicines, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have stage IV or metastatic breast cancer
- You are prescribed endocrine therapy and a CDK4/6 inhibitor
- You are prescribed at least one blood pressure or cholesterol medication
- You sometimes miss doses of your cancer or heart medications, as reported by you or shown in pharmacy records
- You speak English or Spanish
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intervention to help improve how equitably people take their prescribed breast cancer hormone therapy and heart-related prevention medicines. It may help if you have had trouble taking these medications as directed.
This study tests a program to help people with metastatic breast cancer take their oral medications as prescribed. It uses a smartphone app to track and support medication adherence, which may improve treatment outcomes.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
This study tests a new way of monitoring patients with advanced breast cancer who are already taking hormone therapy and a CDK4/6 inhibitor. The goal is to see if remote monitoring can improve care and quality of life.
This trial tests a digital tool (a smartphone app) to help women and men with early breast cancer manage side effects from hormone therapy. The goal is to improve quality of life during treatment.
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.